Non-Radiographic Axial Spondylarthritis

Bimekizumab demonstrates statistically significant improvement over placebo in the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 response at week 16, according to interim results released by UCB.

While there is a cross-section of drugs that are FDA-approved for the treatment of axial spondyloarthritis, clinicians and researchers continue to struggle with axial psoriatic arthritis, according to a presenter at ACR Convergence 2021.

Upadacitinib significantly reduced signs and symptoms of both ankylosing spondylitis and nonradiographic axial spondyloarthritis, as well as improved physical function and disease activity, according to a pair of phase 3 studies from AbbVie.

Given the limited awareness of non-radiographic axial spondyloarthritis, differentiating this disease from radiographic disease and prescribing appropriate therapy remains a key challenge, according to a presentation at the Biologic Therapies Summit.

The FDA has expanded the approval of ixekizumab injection 80 mg/mL to include treatment of active nonradiographic axial spondyloarthritis in patients with objective signs of inflammation.

Radiographic axial spondyloarthritis, or axSpA appears to have less impact on patient-reported outcome measures than the nonradiographic form of the disease, regardless of sex, according to data published in Arthritis Research & Therapy.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

ATLANTA — Ixekizumab combined with conventional background medication is superior to both conventional background medication alone and placebo in improving signs, symptoms and inflammation based on MRI among patients with nonradiographic axial spondyloarthritis, according to data presented at ACR/ARP 2019.